- |||||||||| TP-1287 / Sumitomo Pharma
Trial completion date, Trial termination, Trial primary completion date, Metastases: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Mar 12, 2024
P1, N=74, Terminated,
Trial completion date: Oct 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jan 2024; Sponsor's decision to terminate further development of the program.
- |||||||||| alvocidib (DSP-2033) / Sumitomo Pharma, Zymafos (palifosfamide) / Alaunos Therap, TP-1287 / Sumitomo Pharma
CDK9 inhibition as a potential therapeutic strategy in Ewing sarcoma (Section 9; Poster Board #13) - Mar 14, 2023 - Abstract #AACR2023AACR_8579;
P1
TP-1287 may be a potential therapeutic option for the current regimen in EWS. TP-1287 is being investigated for solid tumors including EWS (clinicaltrials.gov, NCT03604783).
- |||||||||| TP-1287 / Sumitomo Pharma
Trial completion date, Trial primary completion date, Metastases: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Nov 23, 2022
P1, N=80, Recruiting,
TP-1287 is being investigated for solid tumors including EWS (clinicaltrials.gov, NCT03604783). Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
- |||||||||| alvocidib (DSP-2033) / Sumitomo Dainippon
CDK9 as a potential therapeutic target in sarcomas (Section 5) - Mar 9, 2022 - Abstract #AACR2022AACR_4878;
P1
Taken together, alvocidib has shown activity in inhibiting the growth of sarcoma cells and TP-1287 could be a viable therapeutic option targeting the CDK9 pathway in sarcomas. TP-1287 is being investigated for solid tumors including sarcomas (clinicaltrials.gov, NCT03604783).
- |||||||||| TP-1287 / Sumitomo Pharma
Trial completion date, Trial primary completion date, Metastases: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Oct 21, 2020
P1, N=60, Recruiting,
Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Sep 2023 Trial completion date: May 2021 --> Mar 2022 | Trial primary completion date: Feb 2021 --> Dec 2021
- |||||||||| alvocidib (DSP-2033) / Sumitomo Dainippon, TP-1287 / Sumitomo Dainippon
Pharmacodynamic biomarker strategies for CDK9 inhibition (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3860;
P1
Taken together, TP-1287 demonstrated potent cell and tumor growth inhibition in multiple hematological cell lines, including AML and MM. Furthermore, a newly established flow cytometry system for p-RPB1 and MCL-1 to evaluate CDK9 inhibition in human PBMCs was developed, which could be useful as a surrogate biomarker for TP-1287 in clinical trials and warrants further investigation.
- |||||||||| TP-1287 / Sumitomo Dainippon
[VIRTUAL] A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors. (Poster Board 341) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1560;
P1
These findings suggest that TP-1287 is tolerated as a monotherapy in patients with heavily pretreated, relapsed, refractory solid tumors and further clinical development in selected indications is warranted. Research Funding: Tolero Pharmaceuticals, Inc
- |||||||||| Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models (Board 81: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_513;
TP-1287 treatment (1.25 mpk BID) in combination with 100 mpk venetoclax demonstrated 64% tumor growth inhibition in the 22Rv1 CRPC model that was resistant to docetaxel, enzalutamide and venetoclax alone. These data support the potential of TP-1287 to be used in combination with currently available or novel therapies to achieve better efficacy for androgen sensitive and CRPC patients.
- |||||||||| TP-1287 / Sumitomo Pharma
Enrollment open, Metastases: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2018
P1, N=60, Recruiting,
These data support the potential of TP-1287 to be used in combination with currently available or novel therapies to achieve better efficacy for androgen sensitive and CRPC patients. Not yet recruiting --> Recruiting
|
